Advocacy intelligence hub — real-time data for patient organizations
Memorial Sloan Kettering Cancer Center — EARLY_PHASE1
Carl Allen — PHASE2
Memorial Sloan Kettering Cancer Center
Treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute — PHASE2
The Hospital for Sick Children
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Zelboraf
Genentech, Inc.
Zelboraf
(VEMURAFENIB)Orphan drugGenentech, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serine- threonine kinase, inc...
XARELTO
(RIVAROXABAN)standardJanssen Pharmaceuticals, Inc.
Factor Xa Inhibitor [EPC]
12.1 Mechanism of Action XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban...
Matthew Krebs, Dr
The Christie Hospital
Gaurav Goyal, MD
University of Alabama at Birmingham
📍 STONY BROOK, NY
William A Gahl, M.D.
National Human Genome Research Institute (NHGRI)
📍 Bethesda, Maryland
Oussama Abla, MD
The Hospital for Sick Children
Eric Jacobsen, MD
Dana-Farber Cancer Institute
Eli Diamond, MD, M.D
Memorial Sloan Kettering Cancer Center
📍 NEW YORK, NY